An Examination of Federal Sentencing Guidelines' Treatment of MDMA ('Ecstasy')

1 Belmont Law Review 267 (2014)

44 Pages Posted: 17 Aug 2014

Date Written: 2014

Abstract

This Note analyzes the MDMA drug equivalency ratio under the current Guidelines and argues that the ratio is based on incomplete and inaccurate information. Part I of this Note provides an overview of the United States Sentencing Commission (“the Commission”) and the United States Sentencing Guidelines (“the Guidelines”). Part II discusses the rise of MDMA and the legislative response. It also summarizes the Commission’s findings regarding the social and physiological harms of MDMA that formed the basis for the Commission’s decision about the appropriate MDMA drug equivalency ratio. Part III examines the errors in the Commission’s empirical analysis of the harms of MDMA, and in its comparison of the social harms of MDMA to the social harms of other drugs. It also reviews the currently-unresolved federal district court split over whether to defer to the MDMA drug equivalency ratio set forth in the Guidelines. Finally, Part IV calls for a prompt reevaluation of the current MDMA-to-marijuana drug equivalency ratio. This Note concludes that a reevaluation of the MDMA drug equivalency ratio is necessary to ensure horizontal sentencing uniformity, to prevent inefficient use of judicial resources, and to ensure that defendants’ sentences are sufficient but not greater than necessary, as required by 18 U.S.C. § 3553(a)(2).

Keywords: MDMA, Ecstasy, Federal Sentencing Guidelines

Suggested Citation

Hennig, Alyssa, An Examination of Federal Sentencing Guidelines' Treatment of MDMA ('Ecstasy') (2014). 1 Belmont Law Review 267 (2014). Available at SSRN: https://ssrn.com/abstract=2481227

Alyssa Hennig (Contact Author)

Independent

No Address Available

Register to save articles to
your library

Register

Paper statistics

Downloads
113
rank
228,718
Abstract Views
1,714
PlumX